2Suppliers
4Customers
2Debt Items
4Related Chains

Source-Backed Evidence Depth

Lipocine Inc. (LPCN) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

8Total relationships
1Distinct source URLs
4High confidence
0.756Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Lipocine Inc. Suppliers

TickerNameConfidenceEvidence
SPRIASO SPRIASO 85% The Company also agreed to continue providing up to 10 percent of the services of certain employees to Spriaso for a period of time
PSTV Plus Therapeutics, Inc. 62% Reciprocal relationship from PSTV graph: rcised to the extent that immediately following such exercise, the holder would beneficially own greater than 4.99 % (or, at the election of the holder, great…

Lipocine Inc. Customers

TickerNameConfidenceEvidence
SPC-KOREA SPC-KOREA 92% As of March 31, 2026 and March 31, 2025, the Company has recorded deferred revenue of $ 320,000 related to a one-time non-refundable, non-creditable upfront prepayment received from SPC Korea
A-G-P-ALLIANCE-GLOBAL-PARTNERS A-G-P-ALLIANCE-GLOBAL-PARTNERS 62% onsulting fees, accounting and audit fees, director fees, directors’ and officers’ insurance premiums, fees for investor relations services and enhanced business and accounting systems, litigation co…
CAPITAL-RESOURCES CAPITAL-RESOURCES 62% onsulting fees, accounting and audit fees, director fees, directors’ and officers’ insurance premiums, fees for investor relations services and enhanced business and accounting systems, litigation co…
VERITY-PHARMACEUTICALS-INC VERITY-PHARMACEUTICALS-INC 62% obligation to transfer inventory in the future. Revenue associated with this advance payment will be recognized when the inventory is transferred to the customer, which will occur upon shipment of th…

Lipocine Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
LPCN-DEBT Debt stack $2.9M 90% Market cache reports total debt of $2.9M.
LPCN-DEBT-10777 Warrants outstanding: 1375344 90% xbrl warrant detail from xbrl 2024-12-31.

Lipocine Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Lipocine Inc..

Lipocine Inc. Ownership

No ownership data on recordNo major institutional ownership relationships found in our database for Lipocine Inc..

Lipocine Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
PSTV Plus Therapeutics, Inc. 100.00 1 ['supplier']
BDRX Biodexa Pharmaceuticals Plc 50.00 2
BK The Bank of New York Mellon Corporation 50.00 2
NKTR Nektar Therapeutics 50.00 2
🔐
LPCN
Unlock LPCN Supply Chain Data
Verified relationships include:
SPRIASOSPRIASOSupplier85%
PSTVPlus Therapeutics, Inc.Supplier62%
SPC-KOREASPC-KOREACustomer92%
A-G-P-ALLIANCE-GLOBAL-PARTNERSA-G-P-ALLIANCE-GLOBAL-PARTNERSCustomer62%
+4 more relationships locked
Subscribe — View plans →